Capitalizing leadership acumen
for life science innovations

WESTON, Fla.May 1, 2019 /PRNewswire/ -- Variant Pharmaceuticals, Inc., a clinical  stage specialty biopharmaceutical company developing  first-in-class drugs for patients with high unmet medical needs, is  pleased to announce that we have changed our name to ZyVersa Therapeutics effective immediately.

"As our company has evolved, we felt it was important to rebrand it with a name that expresses our vision, our transforming pipeline, and our entrepreneurial spirit," stated Stephen C. Glover, Variant's Co-founder and Chief Executive Officer. "ZyVersa, which was derived from the word versatility, reflects the diverse therapeutic area expertise of our highly experienced leadership team, and our openness to new ideas required to be on the forefront of medical innovation.  It is consistent with our lead pipeline assets, 2HPβCD and our unique inflammasome inhibitor, each of which have potential for multiple indications. And, it conveys our forward-thinking mindset."